Cantor Fitzgerald reissued their overweight rating on shares of Bicara Therapeutics (NASDAQ:BCAX – Free Report) in a report published on Thursday,Benzinga reports. The firm currently has a $13.01 target price on the stock.
Several other analysts also recently commented on the stock. Wedbush reiterated an “outperform” rating and issued a $31.00 price target on shares of Bicara Therapeutics in a research report on Wednesday, February 12th. HC Wainwright upped their price target on shares of Bicara Therapeutics from $42.00 to $45.00 and gave the company a “buy” rating in a research report on Monday, January 27th. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $36.50.
Check Out Our Latest Stock Report on Bicara Therapeutics
Bicara Therapeutics Stock Down 7.0 %
Hedge Funds Weigh In On Bicara Therapeutics
Institutional investors and hedge funds have recently made changes to their positions in the stock. First Turn Management LLC acquired a new position in shares of Bicara Therapeutics during the 3rd quarter worth $14,324,000. Geode Capital Management LLC acquired a new stake in Bicara Therapeutics in the 3rd quarter valued at about $1,239,000. Vestal Point Capital LP acquired a new stake in Bicara Therapeutics in the 3rd quarter valued at about $10,825,000. FMR LLC acquired a new stake in Bicara Therapeutics in the 3rd quarter valued at about $57,913,000. Finally, Braidwell LP acquired a new stake in Bicara Therapeutics in the 3rd quarter valued at about $42,219,000.
About Bicara Therapeutics
Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.
Further Reading
- Five stocks we like better than Bicara Therapeutics
- Consumer Staples Stocks, Explained
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- What Are Dividend Challengers?
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for Bicara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.